Laminin Modulates the Stem Cell Population in LM05-E Murine Breast Cancer Cells Through the Activation of the MAPK/ERK Pathway

Overview

Journal Cancer Res Treat

Specialty Oncology

Date 2017 Jan 6

PMID 28052658

Citations 12

Authors

Damian E Berardi

Diego Raffo

Laura B Todaro

Marina Simian

Affiliations

Soon will be listed here.

Abstract

Purpose: We investigated the effects of laminin on the fraction of cells with self-renewing capacity in the estrogen-dependent, tamoxifen-sensitive LM05-E breast cancer cell line. We also determined whether laminin affected the response to tamoxifen.

Materials And Methods: The LM05-E breast cancer cell line was used as a model for all experiments. Aldehyde dehydrogenase (ALDH) activity, clonogenic and mammosphere assays were performed to measure the effects of laminin on modulation of the stem cell subpopulation. Pluripotent gene expression was analyzed by reverse transcriptase-polymerase chain reaction. The involvement of the mitogen-activated protein kinase (MAPK)/ERK pathway was determined using specific inhibitors. The effects of laminin on the response to tamoxifenwere determined and the involvement of α6 integrin was investigated.

Results: We found that pretreatment with laminin leads to a decrease in cells with the ability to form mammospheres that was accompanied by a decrease in ALDH activity. Moreover, exposure of mammospheres to laminin reduced the capacity to form secondary mammospheres and decreased the expression of Sox-2, Nanog, and Oct-4. We previously reported that 4-OH-tamoxifen leads to an increase in the expression of these genes in LM05-E cells. Treatment with signaling pathway inhibitors revealed that the MAPK/ERK pathway mediates the effects of laminin. Finally, laminin induced tamoxifen resistance in LM05-E cells through α6 integrin.

Conclusion: Our results suggest that the final number of cells with self-renewing capacity in estrogen-dependent breast tumors may result from the combined effects of endocrine treatment and microenvironmental cues.

Citing Articles

Extracellular matrix shapes cancer stem cell behavior in breast cancer: a mini review.

Li L, Tang Y, Qiu L, Li Z, Wang R Front Immunol. 2025; 15():1503021.

PMID: 39850890 PMC: 11754286. DOI: 10.3389/fimmu.2024.1503021.

The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer.

Yuan J, Yang L, Li Z, Zhang H, Wang Q, Huang J Front Endocrinol (Lausanne). 2023; 14:1261283.

PMID: 37900137 PMC: 10611521. DOI: 10.3389/fendo.2023.1261283.

Polymeric immunoglobulin receptor suppresses colorectal cancer through the AKT-FOXO3/4 axis by downregulating LAMB3 expression.

Zhang D, Huang H, Zheng T, Zhang L, Cui B, Liu Y Front Oncol. 2022; 12:924988.

PMID: 35992840 PMC: 9389318. DOI: 10.3389/fonc.2022.924988.

Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer.

Chen J, Wan R, Li Q, Rao Z, Wang Y, Zhang L Cancer Cell Int. 2021; 21(1):306.

PMID: 34112175 PMC: 8194146. DOI: 10.1186/s12935-021-01999-5.

Upregulation of LAMB1 via ERK/c-Jun Axis Promotes Gastric Cancer Growth and Motility.

Lee H, Kim W, Kang H, Jang J, Choi I, Chun K Int J Mol Sci. 2021; 22(2).

PMID: 33435161 PMC: 7826975. DOI: 10.3390/ijms22020626.

References

Bergamaschi A, Tagliabue E, Sorlie T, Naume B, Triulzi T, Orlandi R . Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol. 2007; 214(3):357-67. DOI: 10.1002/path.2278. View

Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H . Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008; 14(5):518-27. DOI: 10.1038/nm1764. View

Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View

Simoes B, Piva M, Iriondo O, Comaills V, Lopez-Ruiz J, Zabalza I . Effects of estrogen on the proportion of stem cells in the breast. Breast Cancer Res Treat. 2010; 129(1):23-35. DOI: 10.1007/s10549-010-1169-4. View

Benton G, Crooke E, George J . Laminin-1 induces E-cadherin expression in 3-dimensional cultured breast cancer cells by inhibiting DNA methyltransferase 1 and reversing promoter methylation status. FASEB J. 2009; 23(11):3884-95. DOI: 10.1096/fj.08-128702. View

Pontiggia O, Sampayo R, Raffo D, Motter A, Xu R, Bissell M . The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin. Breast Cancer Res Treat. 2011; 133(2):459-71. PMC: 3719875. DOI: 10.1007/s10549-011-1766-x. View

Yang X, Flores L, Li Q, Zhou P, Xu F, Krop I . Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res. 2010; 70(6):2256-63. PMC: 3310185. DOI: 10.1158/0008-5472.CAN-09-4032. View

Piva M, Domenici G, Iriondo O, Rabano M, Simoes B, Comaills V . Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol Med. 2013; 6(1):66-79. PMC: 3936493. DOI: 10.1002/emmm.201303411. View

Saha S, Lo P, Duan X, Chen H, Wang Q . Breast tumour initiating cell fate is regulated by microenvironmental cues from an extracellular matrix. Integr Biol (Camb). 2012; 4(8):897-904. DOI: 10.1039/c2ib20034a. View

10.

Tlsty T . Cancer: whispering sweet somethings. Nature. 2008; 453(7195):604-5. DOI: 10.1038/453604a. View

11.

Pontiggia O, Rodriguez V, Fabris V, Raffo D, Bumaschny V, Fiszman G . Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions. Breast Cancer Res Treat. 2008; 116(2):247-55. DOI: 10.1007/s10549-008-0113-3. View

12.

Ginestier C, Hur M, Charafe-Jauffret E, Monville F, Dutcher J, Brown M . ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2008; 1(5):555-67. PMC: 2423808. DOI: 10.1016/j.stem.2007.08.014. View

13.

Musgrove E, Sutherland R . Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009; 9(9):631-43. DOI: 10.1038/nrc2713. View

14.

Taylor-Weiner H, Schwarzbauer J, Engler A . Defined extracellular matrix components are necessary for definitive endoderm induction. Stem Cells. 2013; 31(10):2084-94. PMC: 3812380. DOI: 10.1002/stem.1453. View

15.

Pujuguet P, Radisky D, Levy D, Lacza C, Bissell M . Trichostatin A inhibits beta-casein expression in mammary epithelial cells. J Cell Biochem. 2001; 83(4):660-70. PMC: 2949289. DOI: 10.1002/jcb.1260. View

16.

Phillips T, McBride W, Pajonk F . The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006; 98(24):1777-85. DOI: 10.1093/jnci/djj495. View

17.

Novaro V, Roskelley C, Bissell M . Collagen-IV and laminin-1 regulate estrogen receptor alpha expression and function in mouse mammary epithelial cells. J Cell Sci. 2003; 116(Pt 14):2975-86. PMC: 2933217. DOI: 10.1242/jcs.00523. View

18.

Raffo D, Berardi D, Pontiggia O, Todaro L, Bal De Kier Joffe E, Simian M . Tamoxifen selects for breast cancer cells with mammosphere forming capacity and increased growth rate. Breast Cancer Res Treat. 2013; 142(3):537-48. DOI: 10.1007/s10549-013-2760-2. View

19.

Prowse A, Chong F, Gray P, Munro T . Stem cell integrins: implications for ex-vivo culture and cellular therapies. Stem Cell Res. 2010; 6(1):1-12. DOI: 10.1016/j.scr.2010.09.005. View

20.

Bissell M, Radisky D . Putting tumours in context. Nat Rev Cancer. 2002; 1(1):46-54. PMC: 2975572. DOI: 10.1038/35094059. View